文献速递妇科

腹腔内贝伐珠单抗治疗化疗耐药上皮性卵巢癌症状性腹水的2期试验

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-02-23

REZOLVE(ANZGOG-1101)是一项2期试验,评估腹腔内贝伐珠单抗(IP-bev)对化疗耐药上皮性卵巢癌(CR-EOC)已停止化疗、恶性腹水在末次穿刺后28天内再积聚患者的疗效。共24例受试者,首次研究穿刺后给予IP-bev 5 mg/kg,后续穿刺可追加给药(间隔≥42天)。竞争风险分析显示穿刺后至再次穿刺或死亡时间(TTP)>42天的比例为77%(95%CI 58-92),首次IP-bev后无穿刺间期较研究前延长4.29倍(95%CI 2.4-5.8),结论为安全、有活性,值得进一步研究作为姑息干预。

要点

  • CR-EOC停止化疗后恶性腹水快速再积聚者,IP-bev 5 mg/kg安全且有延缓再积聚活性。
  • TTP>42天比例为77%(95%CI 58-92),无穿刺间期较前延长4.29倍(95%CI 2.4-5.8)。
  • 中位年龄67岁,多数ECOG 2-3,既往系统治疗中位4.5线,属姑息人群。

核心结论

  • IP-bev对化疗耐药上皮性卵巢癌停止化疗后的复发性恶性腹水安全、有活性,值得进一步研究作为姑息干预。

研究设计与样本

  • 2期试验(REZOLVE,ANZGOG-1101),纳入24例化疗耐药上皮性卵巢癌伴恶性腹水、末次穿刺后28天内再积聚的妇女。
  • 首次研究治疗性穿刺(P0)后给予IP-bev 5 mg/kg,后续穿刺可追加给药,前提是距末次给药≥42天。
  • 主要终点为延缓恶性腹水再积聚的活性,次要终点为安全性和生活质量。

主要发现

  • 24例受试者中位年龄67岁(范围38-86),既往系统治疗中位4.5线(范围1-12),ECOG体能状态0分1例、1分8例、2-3分15例。
  • IP-bev给药次数:1次13例、2次5例、3次2例、4次1例、5次1例。
  • 竞争风险分析显示TTP>42天的比例为77%(95%CI 58-92)。
  • P0至P1或死亡的中位时间为48天(范围8-248)。
  • 首次IP-bev后中位无穿刺间期(P0-P1或死亡)较研究入组前穿刺间期(P-1-P0)高4.29倍(95%CI 2.4-5.8)。

临床怎么用

  • 对化疗耐药上皮性卵巢癌停止化疗后恶性腹水快速再积聚者,可考虑IP-bev 5 mg/kg作为姑息性干预以延缓再穿刺。
  • 后续穿刺时可追加IP-bev,但需确保距末次给药≥42天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian cancer (CR-EOC) who have ceased chemotherapy. Secondary outcomes were safety and quality of life. METHODS: Women with CR-EOC and malignant ascites that reaccumulated within 28 days of their last paracentesis (P-1) were administered IP-bev 5 mg/kg following their first therapeutic paracentesis on study (P0). Additional doses of IP-bev were allowed at each subsequent paracentesis (P1, P2, etc) provided the interval from the last dose was 42 days or greater (median time from first to second therapeutic ascitic drainage). RESULTS: 24 participants (median age 67 years [range 38-86]; median 4.5 lines prior systemic treatment [range 1-12]; ECOG performance status of 0 in 1, 1 in 8, and 2-3 in 15) were recruited. The doses of IP-bev administered were 1 in 13 participants, 2 in 5, 3 in 2, 4 in 1, and 5 in 1. The proportion with a TTP of >42 days using competing risk analysis was 77% (95% CI 58-92). Median time from P0 to P1 or death was 48 days (range 8-248). Median paracentesis-free interval (P0-P1 or death) was 4.29-fold (95% CI 2.4-5.8) higher following a first dose of IP-bev compared with the time between paracenteses prior to study entry (P-1-P0). CONCLUSION: IP-bev was safe, active, and warrants further study as a palliative intervention for recurrent ascites in CR-EOC patients receiving best supportive care.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sjoquist KM, Espinoza D, Mileshkin L, et al. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol Oncol. 2021. PMID: 33637349. doi:10.1016/j.ygyno.2021.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。